（原标题：医疗器械业务加速但诊断"失速" 雅培(ABT.US)业绩不及预期） 智通财经APP获悉，美国医疗保健领域领导者雅培(ABT.US)在美股周三盘前所公布的季度营收低于华尔 街分析师预期，主要因市场对其医疗器械产品的强劲需求未能抵消其医疗诊断与营养品业务的疲弱趋 势。在业绩指引中，该公司管理层小幅下调每股收益展望上限，凸显特朗普政策不确定性带来的负面预 期。受到最新业绩带来的负面影响，该公司股价在美股盘前交易中下跌近3%。 该公司表示，现在预计全年调整后每股收益将在5.12美元至5.18美元区间，相比之下先前的区间则为 5.10美元至5.20美元，凸显出雅培管理层因关税与监管政策不确定性二下调每股收益上限预期。 上个月，特朗普政府根据《美国反垄断法》第232条对医疗器械进口展开全面调查，引发了对于该行业 征收新关税的可能性，并加强了对外国医疗供应链体系的审查。该公司还表示，其此前对今年关税影响 规模低于 2 亿美元的预期没有变化。 雅培Q3医疗器械业务的高景气(如糖尿病与心血管器械)虽稳健，但是未能完全对冲上述拖累。此外，雅 培业绩指引微幅收窄/重申销售额中枢，说明该公司业绩层面的问题更多是产品组合与周 ...

Summary of the Conference Call on the Wearable Health Monitoring Devices Industry Industry Overview - The conference call focused on the **wearable health monitoring devices industry** in China, highlighting its rapid growth and potential to transition from a technological novelty to a necessity for the general public [1][2][3]. Key Points and Arguments 1. **Explosive Growth**: The wearable health monitoring devices industry is experiencing explosive growth, driven by several core factors [1]. 2. **Market Size Expansion**: The market size is expected to exceed **200 billion** yuan, indicating a significant expansion [1]. 3. **Key Growth Engines**: The industry must overcome three major challenges to achieve a transformation from a tech consumer product to a public health necessity [1]. 4. **Health Issues in the Workforce**: Increasing health issues among Chinese workers, with **90.5%** of employees facing sleep deprivation, are driving the industry's growth [3][4]. 5. **Aging Population and Chronic Diseases**: The acceleration of aging and the rising prevalence of chronic diseases are also significant drivers for the industry [4][5]. 6. **Product Evolution**: Non-invasive blood glucose monitors are evolving from mere health monitoring tools to becoming integral to health management systems connecting families with healthcare providers [5]. 7. **Market Growth Trajectory**: From **2020 to 2024**, the market size is projected to grow from **140 billion** yuan to **150 billion** yuan, despite short-term fluctuations due to economic conditions [5]. 8. **Differentiated Development Paths**: Consumer-grade products (e.g., smart bands, watches) and medical-grade products are developing along different paths [5][6]. 9. **Rapid Market Growth**: The market is expected to grow from **51.8 billion** yuan in 2020 to **116.6 billion** yuan by 2029, with products like Huawei Watch D receiving medical device certification [6]. 10. **Industry Structure**: The industry operates on a three-tier structure involving upstream suppliers, midstream manufacturers, and downstream sales channels [6][7]. 11. **Sensor Market Growth**: The sensor market is projected to grow at a **15%** compound annual growth rate, expected to exceed **500 billion** yuan by 2026 [6]. 12. **Market Share Dynamics**: The online and offline markets for wearable devices are showing a trend towards balance, with smartwatches dominating offline sales [7]. 13. **Consumer Market Dominance**: Major technology companies like Huawei, Apple, and Xiaomi dominate the consumer market, leveraging strong R&D capabilities [8]. 14. **Integration of Medical Functions**: Some medical companies are attempting to enter the consumer market, but face challenges in brand recognition and user perception [8]. 15. **Technological Advancements**: The industry is undergoing significant technological changes, with AI advancements expected to enhance device capabilities [9]. 16. **Healthcare Integration**: Wearable devices are becoming crucial nodes in remote healthcare systems, promoting a shift from disease-centered to health-centered paradigms [9][10]. 17. **Case Studies**: The strategies of key players like Huawei and medical device companies illustrate the competitive landscape and strategic choices within the industry [10]. Other Important Insights - The industry is supported by a comprehensive policy framework that includes technological innovation, standardization, and integration with healthcare [3]. - The evolution of wearable devices is not just a technological advancement but also a shift in healthcare paradigms, emphasizing preventive health management [9][10]. This summary encapsulates the key insights and developments discussed in the conference call regarding the wearable health monitoring devices industry, providing a comprehensive overview of its current state and future potential.

Financial Data and Key Metrics Changes - Global sales for the first quarter of 2025 were $3.2 billion, down 0.1% compared to the first quarter of 2024, with a 1.5% decrease due to foreign currency exchange and a 1.2% growth from acquisitions [26][27] - GAAP operating margin improved by 81 basis points to 5.53%, while non-GAAP operating margin increased by 14 basis points to 7.25% [27] - GAAP net income for the first quarter was $110 million or $0.88 per diluted share, compared to $93 million or $0.72 per diluted share in the prior year [27] - Non-GAAP net income was $143 million or $1.15 per diluted share, compared to $143 million or $1.10 per diluted share in the prior year [28] Business Line Data and Key Metrics Changes - U.S. Dental merchandise sales grew low single digits, while U.S. Dental equipment sales declined 8.9% due to a deferral of approximately $20 million in sales from Q4 2023 to Q1 2024 [30][31] - U.S. Medical distribution sales grew by 4.7% after excluding PPE products and COVID test kits, with Home Solutions business experiencing a total sales growth of 23% [31][32] - Global Specialty Products Group saw constant currency sales growth of 4.3%, with strong growth in the DACH region and Latin America [32][33] Market Data and Key Metrics Changes - International Dental merchandise sales grew 1.1% in constant currency, while international Dental equipment sales grew 4.3% driven by strong growth in Canada and Central Europe [32] - The U.S. implant market was slightly down, but the company maintained market share and saw strong sales growth in Europe, particularly in Germany [21][33] Company Strategy and Development Direction - The company is advancing its Bold plus One strategic plan, focusing on operational efficiency, enhancing customer experience, and growing its digital footprint [9][10] - The establishment of two main business units, the Global Distribution and Value Added Service Group and the Global Technology Group, aims to streamline operations and improve performance [9][10] - The company expects high single-digit to low double-digit earnings growth by executing its strategic initiatives [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the business despite a slow start in January due to weather-related events, with sales performance improving in February and March [6][8] - The overall mood in the dental and medical markets is stable, with increased patient traffic and investment in practices [50][62] - Management acknowledged the potential impact of tariffs but believes current actions will mitigate financial effects [24][58] Other Important Information - The company repurchased approximately 2.3 million shares at an average price of $71.58 per share, totaling $161 million [34] - The company maintains its 2025 financial guidance, expecting non-GAAP diluted EPS in the range of $4.80 to $4.94 [38] Q&A Session Summary Question: Can you talk about the dollar's impact on revenue guidance? - The company experienced a 1.5% headwind from foreign exchange in Q1, but expects foreign exchange to be neutral for the remainder of the year [44][45] Question: What is the current environment in April? - April showed decent performance, with stable traffic in dental distribution and solid growth in medical sales due to increased patient visits [47][50] Question: Are there any adjustments to guidance inputs? - The company maintains its sales guidance, expecting growth to be largely internally generated with foreign exchange being neutral [56] Question: How is the company managing tariff impacts? - The company is diversifying sourcing to mitigate tariff impacts and is working closely with suppliers and customers [58][59] Question: What is the current state of the dental capital equipment market? - Demand for dental equipment remains healthy, with no significant declines in orders observed [109]

天键电声股份有限公司 首次公开发行股票并在创业板上市发行公告 保荐人（主承销商）： 特别提示 天键电声股份有限公司（以下简称"天键股份"、"发行人"或"公司"）根据中 国证券监督管理委员会（以下简称"证监会"）《证券发行与承销管理办法》（证监 会令[第 208 号]）（以下简称"《管理办法》"）、《首次公开发行股票注册管理办法》 （证监会令[第 205 号]）（以下简称"《注册办法》"），深圳证券交易所（以下简称 "深交所"）《深圳证券交易所首次公开发行证券发行与承销业务实施细则》（深证 上[2023]100 号，以下简称"《业务实施细则》"）、《深圳市场首次公开发行股票网 上发行实施细则》（深证上〔2018〕279 号）（以下简称"《网上发行实施细则》"）、 《深圳市场首次公开发行股票网下发行实施细则（2023 年修订）》（深证上〔2023〕 110 号）（以下简称"《网下发行实施细则》"）、《深圳证券交易所创业板投资者适 当性管理实施办法（2020 年修订）》（以下简称《投资者适当性管理办法》）和中 国证券业协会（以下简称"证券业协会"）《首次公开发行证券承销业务规则》（中 证协发〔2023〕18 号）（ ...